Next Article in Journal
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
Next Article in Special Issue
Clinical Study on the Emotional Intervention of Patients with Asymptomatic and Mild Novel Coronavirus (COVID-19)
Previous Article in Journal
A Novel Implant for Superior Pubic Ramus Fracture Fixation—Development and a Biomechanical Feasibility Study
Previous Article in Special Issue
Using Text Mining and Data Visualization Approaches for Investigating Mental Illness from the Perspective of Traditional Chinese Medicine
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 59
Issue 4
10.3390/medicina59040741
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Research Progress on the Pharmacodynamic Mechanisms of Sini Powder against Depression from the Perspective of the Central Nervous System

by
Zhongqi Shen
1,
Meng Yu
2 and
Zhenfei Dong
1,*
1
College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
2
Innovative Institute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
*
Author to whom correspondence should be addressed.
Medicina 2023, 59(4), 741; https://doi.org/10.3390/medicina59040741
Submission received: 1 March 2023 / Revised: 6 April 2023 / Accepted: 7 April 2023 / Published: 10 April 2023
(This article belongs to the Special Issue From the Perspective of Traditional Chinese Medicine: Clinical Presentations and Treatment of Depression)
Browse Figure
Review Reports Versions Notes

Abstract

:
Depression is a highly prevalent emotional disorder characterized by persistent low mood, diminished interest, and loss of pleasure. The pathological causes of depression are associated with neuronal atrophy, synaptic loss, and neurotransmitter activity decline in the central nervous system (CNS) resulting from injuries, such as inflammatory responses. In Traditional Chinese Medicine (TCM) theory, patients with depression often exhibit the liver qi stagnation syndrome type. Sini Powder (SNP) is a classic prescription for treating such depression-related syndrome types in China. This study systematically summarized clinical applications and experimental studies of SNP for treatments of depression. We scrutinized the active components of SNP with blood–brain barrier (BBB) permeability and speculated about the corresponding pharmacodynamic pathways relevant to depression treatment through intervening in the CNS. Therefore, this article can enhance our understanding of SNP’s pharmacological mechanisms and formula construction for depression treatment. Moreover, a re-demonstration of this classic TCM prescription in the modern-science language is of great significance for future drug development and research.

1. Introduction

Depression is one of the leading risk factors for suicide, affecting more than 300 million people worldwide [1]. The pathological causes of depression can vary, as it is associated with neuronal atrophy, synaptic loss, and a decline in relevant neurotransmitter activity in the prefrontal cortex and hippocampus [2,3,4,5]. Although current anti-depression treatments can be effective, effective action requires up to 6 weeks with multiple therapeutic agents, while side effects are observed [6]. Selective serotonin reuptake inhibitors (SSRIs), a typical type of anti-depression drug via restoring neuroplasticity, may lead to adverse effects, such as headache, insomnia, fatigue, and somnolence, which eventually increase suicide rates in adolescents with depression in the early stages of treatment [7,8,9,10]. Hence, novel therapeutic options are needed for the safe and effective treatment of depression.
The onset and progression of depression are intimately associated with the central nervous system (CNS). For instance, neuron cell damage caused by inflammation and the neurotransmitter dysfunction represented by a decrease in 5-hydroxy tryptamine (5-HT) undoubtedly play considerable roles in the process of depression [11,12]. These findings direct the paths of antidepression drug discovery, namely, that the pharmaceutical components should exhibit the capability to cross the blood–brain barrier (BBB) and interfere with the relevant biological pathways, including combating inflammatory damage, inhibiting neuronal apoptosis, restoring synaptic plasticity, and increasing neurotransmitter activity [13,14].
Traditional Chinese Medicine (TCM) is a time-proven medical discipline that originated from Chinese philosophy and religion and is focused on maintaining or restoring holistic balance in the body [15]. Intrinsically, its efficacy relies on the synergic effects of herbs with empirical evidence [16]. Corresponding with the buildup of scientific perspectives on TCMs, their usages have been extensively implemented in medical management for diseases, including depression, due to their multi-component, -target, and -pathway nature with fewer reported side effects [17]. In TCM theory, patients with depression often express liver qi stagnation. Sini Powder (SNP), a classical prescription in the Treatise on Febrile Diseases by Zhang Zhongjing in the Han Dynasty, is the standard prescription used to treat depression for this syndrome type by dispersing and relieving stagnated liver qi [18]. Consistently, SNP has been widely used in the clinic to combat depression with significant efficacy and a low incidence of adverse effects, showing good research value and development prospects.
Network pharmacology, as part of bioinformatics technology, integrates system biology with computational biology [19], revealing the relationship between molecular monomers and specific diseases by comprehensively studying and expanding their putative intersected targets [20]. Herein, we identified the active components of SNP with BBB permeability, along with their relevant enriched biological pathways. Then, we reviewed and summarized the previous studies based on these results, which can reflect the pharmacodynamical mechanisms of SNP in the treatment of depression regarding the CNS. Together, these would not only improve the safety and efficacy of related therapeutic agents but also lay the foundation for future mechanistic studies and anti-depression drug development.

2. Sini Powder against Depression

2.1. Advantages of Sini Powder against Depression

Chaihu (CH, Radix Bupleuri), Zhishi (ZS, Aurantii Fructus Immaturus), Baishao (BS, Paeoniae Radix Alba), and Gancao (GC, Licorice) are included in SNP [21]. Multiple clinical trials demonstrated that SNP can effectively modulate the circadian rhythms of depression patients [22], demonstrating therapeutic effects on several types of depression, including diabetes with depression [23], functional dyspepsia with depression [24], and post-stroke depression [25]. Animal experiments proved that SNP can regulate the hypothalamic–pituitary–adrenal (HPA) axis, and a single pretreatment extract can relieve the increases in serum corticosterone (CORT) and plasma corticotropin-releasing hormone (CRH) levels induced by acute stress, as well as elevating the mRNA expression of the hippocampal glucocorticoid receptor to combat depression [26]. Similar prescriptions of SNP can also interfere with neurogenesis, up-regulate tight BBB connections, and balance the fibrinolytic system to reduce depressive behavior [27]. Experiments in rats have shown that SNP can inhibit the activation of inflammatory responses mediated by the nuclear factor-kappa B (NF-κB) pathway, as well as inflammasomes, such as nod-like receptor protein 3 (NLRP3), interleukin (IL)-1β, and IL-6 [28]. In addition, SNP can also prolong sleep time and alleviate insomnia mood disorder [29].

2.2. Therapeutic Effects of Sini Powder Herbs against Depression

The Chaihu and Baishao (CH–BS) drug pair is one of the most accepted combinations among the multiple TCM classical antidepressant prescriptions. Studies have shown that the antidepressant effects of CH–BS are significantly better than those of CH or BS alone in a sucrose preference test (SPT), open field test (OFT), and forced swim test (FST) [30]. The CH–BS drug pair can reduce the generation of peroxidation products and down-regulate NLRP3 inflammasome expression, IL-1β, IL-6, and tumor necrosis factor (TNF)-α secretion to treat depression by combating inflammatory response and oxidative stress damage [31]. A single application of CH also has antidepressant effects, with a meta-analysis on CH proving that the efficacy and safety aspects of combining CH with antidepressants were generally superior to single-antidepressant treatment [32].

3. Pharmacodynamic Mechanisms of Active Components of SNP

3.1. Screening of Active Components Crossing the BBB

We adopted a network pharmacology approach to confirm the active components that can cross the BBB. The SNP components were collected from the Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP, https://old.tcmsp-e.com/tcmsp.php (accessed on 14 December 2022)). Oral bioavailability (OB) is one of the most considerable pharmacokinetics parameters, and the higher the OB value the better the drug-likeness (DL) of the active component [33]. The Caco-2 screening assay is a valuable tool for testing compounds for intestinal permeability [34]. In this study, the criteria of OB ≥ 30%, DL ≥ 0.18, and Caco-2 ≥ −0.4 were used to screen the active components obtained from the TCMSP [35].
The canonical SMILES of all active components obtained from the TCMSP database were imported into the Swiss ADME (http://www.swissadme.ch/ (accessed on 14 December 2022)) website to analyze whether they can cross the BBB. Finally, a total of 40 active SNP components crossing the BBB were screened out, and the results are listed in Table 1.

3.2. Active Components of Zhishi

Sinensetin (MOL001803) can inhibit the activation of the toll-like receptor 4 (TLR4) and NF-κB pathways; significantly inhibit the production of pro-inflammatory mediators, such as TNF-α and IL-6; promote the activation of anti-inflammatory cytokines, such as IL-4, IL-10, IL-13, and TGF-β; and also reduce the production of MMP9 and MMP13 [36,37], thereby protecting the degraded extracellular matrix and attenuating cell apoptosis [38]. Additionally, it can decrease apoptosis by elevating the phosphorylation of phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt) and activating the PI3K-Akt pathway [39]. Sinensetin also attenuates the activation of the mitogen-activated protein kinase (MAPK) pathways in brain microvascular endothelial cells by decreasing the phosphorylation of extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 subclasses, and can up-regulate peroxisome-proliferators-activated receptor gamma (PPARG) system activity, thereby restoring neuroplasticity and neurogenesis [40,41].
Didymin (MOL005849) inhibits the NF-κB pathway through the MAPK pathway, decreases NLRP3 inflammasome levels, and down-regulates the expression of inflammatory factors, such as IL-1β, IL-6, and TNF-α, as well as monocyte chemotactic protein 1 (MCP-1) [42]. In vivo and vitro experiments have proven that its use in pretreatment can attenuate apoptosis resulting from inflammatory response damage through decreasing Bax and Caspase-3 levels and increasing the Bcl-2 level [43]. Didymin can also activate the PPAR signaling pathway, increase the expression of PPARG to protect neuronal cells, and activate the PI3K-Akt-GSK-3β pathway to repair synaptic plasticity [44,45].
Tetramethoxyluteolin (MOL007879) can inhibit the focal inflammation in the brain caused by the cytokine of mast cells and microglia, which results from the co-stimulation of CRH in cooperation with IL-33, to exert neuroprotective effects [46]. Isosinensetin (MOL013277) also inhibits the NF-κB pathway through the MAPK pathway to attenuate inflammatory damage [47].

3.3. Active Components of Baishao

Palbinone (MOL001919) can significantly reduce the production of pro-inflammatory cytokines IL-18 and IL-1 and improve the accumulation of nuclear factor erythroid-2-related factor 2 (Nrf2), thereby modulating inflammation-induced, depressive-like responses through the Nrf2-NLRP3 pathway [48].
Paeoniflorin (MOL001925) significantly inhibits the secretion of inflammatory factors, such as IL-6ˏ TNF-α [49]. In vitro and vivo studies demonstrated that paeoniflorin can decrease Bax and Caspase-3 expression levels, increase the Bcl-2 expression level, and inhibit neuronal apoptosis by activating the PPARG system [50,51]. Paeoniflorin can also increase 5-HT content in the serum of depression model rats to restore neurotransmitter function [52]. Furthermore, the data have indicated that paeoniflorin can effectively improve the depression-like state in depression model rats, the behavioral profile and HPA axis can be significantly regulated in the pharmacodynamic index, and the metabolic pathways of the related indexes can be significantly recovered in the metabolomics analysis—with the mechanism possibly related to reductions in the serum levels of ACTH, CORT, and CRH [53,54]—to intervene in the neuroendocrine immune system and metabolic pathways [55]. In addition, paeoniflorin can activate the downstream Nrf2 pathway through the PI3K-Akt pathway to combat oxidative stress [56,57]. Additionally, paeoniflorin can also reduce the protein expression of ERK, JNK, and p38, and the potential mechanism may be related to the inhibition of the TGF-β-activated kinase 1 (TAK1)-MAPK signaling pathway [58,59].

3.4. Active Components of Gancao

Formononetin (MOL000392) attenuates the over-production of cytokines and inflammatory mediators; decreases the serum levels of inflammatory factors, such as TNF-α and IL-6; and inhibits the IL-1β-induced activation of the NF-κB pathway [60]. It also inhibits the expression of cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS), as well as the synthesis of catabolic factors, such as matrix metalloproteinases (MMPs) [61], to combat the damage to cells caused by inflammation and oxidative stress. Formononetin could also interfere with the expression level of the 5-HT receptor, modulating 5-HT activity [62]. Formononetin can up-regulate the PI3K-Akt pathway by activating the downstream regulator of the phosphatase and tensin homolog (PTEN) to improve neuronal atrophy [63,64] and depressive behavior in the mouse model of depression by inhibiting the activity of PI3K-Akt-GSK-3β and the downstream Notch1 signaling pathway [65]. Furthermore, formononetin also exerts anti-neurodegenerative effects by inhibiting apoptosis through decreasing MAPK phosphorylation [66].
Licochalcone A (MOL000497) potently inhibits the release of inflammatory factors TNF-α, IL-4, IL-5, IL-6, and IL-13 [67,68]. It inhibits the activity of NLRP3 inflammatory bodies by reducing the production of IL-1β, directly binds to the accessory proteins of TLR4, and inhibits TLR4 pathway activation and inflammatory cytokine induction, significantly reducing immune cell infiltration to exert anti-inflammatory and neuroprotective effects [69,70]. Licochalcone A could interfere with the 5-HT receptor expression level, modulating 5-HT activity [71], as well as intervene in the Akt and NF-κB pathways by down-regulating MAPK expression, which inhibits the cell migration and invasion resulting from inflammatory response [72,73]. It can also up-regulate PPARG protein expression [74].
Treatment with vestitol (MOL000500) can reduce the activity of NF-κB and ERK pathways, decrease the levels of pro-inflammatory factor IL-6, IL-4, TNF-α, TGF-β, and NO synthase, promote the release of anti-inflammatory factor IL-10 to combat oxidative stress and inflammatory damage, and inhibit leukocyte migration [75]. Maackiain (MOL001484) can reduce the secretion of MCP-1 and TNF-α, as well as inhibit the NF-κB pathway. In parallel, it can also up-regulate the expression of Bcl-2; down-regulate the expression of Bax, Caspase-9, and Caspase-3; and inhibit the apoptosis resulting from inflammatory responses [76].
Liquiritigenin (MOL001792) has been shown to have anti-inflammatory, anti-hyperlipidemic, and antioxidant properties, which can inhibit the activation of the NF-κB and NLRP3 inflammatory pathways [77]. It has also been shown to have ameliorative effects on the HPA axis [78]. Experiments demonstrated that liquiritigenin can reduce the depressive behavior of mice through its anti-inflammatory and neuroprotective effects, and it may also treat chronic depression through the brain-derived neurotrophic factor (BDNF) signaling pathway mediated by the PI3K-Akt-mTOR signaling pathway [78,79,80].
Medicarpin (MOL002565) was experimentally demonstrated to be able to inhibit CUMS-induced neuro-inflammation through hampering NF-κB pathway activation [81], and inhibit brain microvascular endothelial cell injury by activating the PI3K-Akt-FOXO pathway [82]. Shinpterocarpin (MOL004891) was reported to have antioxidant, anti-inflammatory, and anti-cytotoxic activities, as well as exhibiting significant binding activity against the PPARG ligand [83,84].
Glabridin (MOL004908) can significantly down-regulate the expression of pro-inflammatory mediators, such as IL-1β and TNF-α; prevent the decline in Nrf2 activity and inhibit TLR4 activation; and up-regulate Bax expression, reversing inflammation-induced apoptosis [85,86]. Additionally, it can inhibit the NF-κB pathway through the MAPK pathway and activate the PI3K-Akt-GSK-3β pathway to repair synaptic plasticity [87,88]. Glabridin can also suppress inflammation and oxidative stress injury by activating the PPARG system, inhibiting pro-inflammatory factor expression, and elevating anti-inflammatory factor expression, thus reducing the level of peroxidation products and increasing the level of peroxidases [89].

4. Pharmacodynamic Pathways of Active Components of SNP

To obtain the pharmacodynamic pathways of SNP in CNS treatments, we speculated on the potential targets of active components and applied enrichment analysis to obtain the pharmacodynamic pathways that the potential targets may act on. After entering into the CNS, the active components should be able to treat depression effectively by intervening in the relevant pathways.

4.1. Acquisition of Potential Targets against Depression

Depression targets were collected from seven databases, including DisGeNET, GeneCards, NCBI, OMIM, UniProt, TTD, and DrugBank, with “depression” as the keyword, while 7948 depression targets were obtained after de-duplicating the results. In total, 695 active-component targets that can cross the BBB were found by importing the canonical SMILES into the SwissTargetPrediction website. In total, 559 targets that intersected depression targets and active components were considered the potential SNP targets against CNS depression.

4.2. Enrichment Analyses

The efficacy of TCM is represented by the synergy effects of potential targets; however, experimental validation would require additional work, thus hindering our progression with scrutinizing the TCM target–effects relationship spectrum. KEGG enrichment analysis shows considerable numbers of signal pathways for the synergy effects of potential targets. Therefore, we need to step-wisely narrow our study objects through KEGG analysis. The MCODE algorithm can detect densely connected regions that are likely to represent molecular complexes in large PPI networks based solely on connectivity data [90]. Both are common approaches to studying the relationship between TCM prescriptions and their efficacy against diseases.
The Metascape online analysis website was used for the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. The top 20 KEGG pathways of SNP were sorted by their p-values (shown in Figure 1A), and the results were mainly concerned with the neuroactive ligand–receptor interaction, calcium signaling pathway, and MAPK signaling pathway. Given the highly distracting capacity of cancer pathways, relevant cancer pathways were excluded, accordingly. For the MCODE analyses, the active components that can cross the BBB and potential targets were imported into Cytoscape 3.9.1 software (Boston, MA, USA), and the MCODE plug-in was used to identify the top three clusters, which were screened out (Figure 1B). The details of each cluster are listed in Table 2, and the targets of each cluster are listed in Supplementary Materials Table S1. According to the results, the clusters were related to apoptosis, the cell cycle, and the PI3K-Akt signaling pathway.

5. Discussion and Limitations

Neuroinflammation and its damage are well-known to play a considerable role in the pathological progression of depression. Additionally, the effects of the SNP active components that we reviewed on the CNS are also mostly associated with anti-inflammation and the repair of inflammatory damage. It is worth mentioning that the pharmacological pathway results obtained through enrichment analysis also echoed the review content in the previous text. It is also of concern that the NF-κB pathway, the classical inflammatory signaling pathway, accounted for a significant part of the treatment of depression using SNP. Although the results of the enrichment analysis were not directly linked to the NF-κB pathway, other pathways closely related to it were oriented. Detailed information is discussed below.
According to the KEGG pathway enrichment analysis results, neuroactive ligand–receptor interactions are associated with the transmission of neurotransmitters across synapses, represented by 5-HT [91,92]. The BDNF-related pathways can influence 5-HT activity by acting on the expression of its receptor to restore normal neurotransmitter function [93,94,95]. The PPARG system can rapidly sense cellular stress responses and protect glial cells, neuronal cells, and cerebrovascular endothelial cells in the CNS, as well as considerably increasing BDNF levels in brain regions to promote neuroplasticity and neurogenesis [96,97]. The HPA axis has been implicated in the pathophysiology of multiple emotional and cognitive disorders by data from different neuroscience disciplines [98,99], including correcting the abnormal secretion of adrenocorticotropic hormone (ACTH) [100,101], CORT [102,103], and CRH [104]. Additionally, the hypersecretion of hormones can lead to the impairment of 5-HT receptor activity [105]. Studies have shown that stress plays a key role in the pathogenesis of depression, and the stress-induced MAPK pathway includes the ERK, JNK, and p38 subclasses. ERK expression would be involved in the intermediate process of BDNF expression, and the inhibition of ERK in the prefrontal cortex and hippocampus leads to depression-like behavior [106,107]. Abnormal phosphorylation of JNK can promote apoptosis and inhibit neural synapse regeneration, leading to depression [108]. Additionally, the activation of p38 MAPK is closely related to stress-induced aversive responses [109].
Additionally, regarding the MCODE results, stress is well-known to exert deleterious effects on neuronal apoptosis and neuroplasticity by affecting multiple cellular cascades, which can also lead to structural plasticity changes in the brain [110]. The regulation of the cell cycle is essential for apoptosis [111]. Neuronal apoptosis decline and the enhancement of neuronal proliferation after cell cycle regulation have proven to be effective in treating depression [112]. In addition, there are multiple factors responsible for the occurrence of depression, such as damage due to neuroinflammation. The NF-κB pathway leads to neuroinflammation, and most anti-inflammation pharmacodynamic pathways are related to it [113,114]. Activation of the PI3K-Akt cell survival pathway can inhibit the downstream NF-κB pathway [115], inhibit the forkhead box protein O 1 (FoxO1) pathway to attenuate the apoptosis resulting from neuro-inflammation [116], and inhibit the glycogen synthase kinase-3β (GSK-3β) pathway to restore synaptic plasticity [117,118]. The PI3K-Akt and MAPK pathways are closely linked and, together, modulate neuronal cell survival [119,120].
Despite encouraging findings, certain limitations remain. First, there have been few clinical trials targeting SNP for the treatment of depression, especially those related to the CNS. The reason might be the poor BBB penetration rate. We expect more clinical trials regarding SNP treatment for depression to emerge in follow-up studies, preferably in relation to the active components that we have screened out that can enter into the CNS. Second, our study was mainly based on the current databases, and given that the number of TCM studies on depression is still insufficient, it is inevitable that the absence of herbal components in the SNP may have an impact on the pharmacodynamic mechanism results of the enrichment analysis. Finally, although we have speculated on the active components in SNP that can enter the CNS, further validation experiments are still required, such as the HPLC detection of active components using rat cerebrospinal fluid extracted after SNP treatment.

6. Conclusions and Prospects

Because the pathological process of depression in the CNS is incompletely understood, the development of novel medicines remains a serious challenge. SNP, a classic TCM prescription, is widely utilized to combat depression in clinical applications with obvious efficacy and fewer reports of side effects. In this study, we obtained active SNP components that can intervene in the CNS, and systematically reviewed and speculated on their antidepressant pharmacodynamic mechanisms. It is quite evident that most of the active components have been confirmed to possess significant anti-inflammatory properties. Given that inflammatory response occupies a very considerable position in the pathological process of depression and has a close association with other etiological factors, we believe that exploring the anti-inflammatory properties of these active components will be a powerful direction for SNP follow-up studies to take in determining its efficacy as an antidepressant.
Advances in modern biological technology will keep accelerating the research on SNP’s mechanisms against depression, improving the safety and efficacy of the related therapeutic agents. After further identifying the effective components in SNP that can intervene in the CNS through molecular docking and molecular dynamics simulation, in the future, we will encourage further attention to improving the efficiency with which these components enter the CNS, such as through nanomaterial wrapping transport, thereby increasing the efficacy of SNP as an antidepressant. In addition, more quantitative detection of the active components through technical means, such as network pharmacology and HPLC, which can more rigorously determine the standard composition of SNP in clinical applications and experimental studies, will benefit the subsequent research on, and industrialization of, SNP. Moreover, TCM prescriptions usually have characteristics of being homologous to food, which can benefit the health industry to some extent through the confirmation and extraction of the pharmacodynamic components of SNP and its subsequent application in combination with diet.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/medicina59040741/s1, Table S1. Targets of top 3 MCODE clusters.

Author Contributions

Writing-original draft preparation, Z.S.; writing-review and editing, M.Y. and Z.D. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Natural Science Foundation of Shandong Province (ZR2019BH017 and ZR2021LZY042) and the Shandong Province College Youth Creation and Talent Introducing and Nurturing Program (2019KJK013).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data used to support the findings of this study are included within the article and Supplementary Materials.

Conflicts of Interest

No potential conflict of interest were reported by the authors.

References

  1. Ekinci, G.N.; Sanlier, N. The relationship between nutrition and depression in the life process: A mini-review. Exp. Gerontol. 2023, 172, 112072. [Google Scholar] [CrossRef]
  2. Gujral, S.; Aizenstein, H.; Reynolds, C.F., 3rd; Butters, M.A.; Erickson, K.I. Exercise effects on depression: Possible neural mechanisms. Gen. Hosp. Psychiatry 2017, 49, 2–10. [Google Scholar] [CrossRef]
  3. Kraus, C.; Castrén, E.; Kasper, S.; Lanzenberger, R. Serotonin and neuroplasticity—Links between molecular, functional and structural pathophysiology in depression. Neurosci. Biobehav. Rev. 2017, 77, 317–326. [Google Scholar] [CrossRef] [Green Version]
  4. Duman, R.S.; Aghajanian, G.K. Synaptic Dysfunction in Depression: Potential Therapeutic Targets. Science 2012, 338, 68–72. [Google Scholar] [CrossRef] [Green Version]
  5. Price, R.B.; Duman, R. Neuroplasticity in cognitive and psychological mechanisms of depression: An integrative model. Mol. Psychiatry 2019, 25, 530–543. [Google Scholar] [CrossRef]
  6. Marwaha, S.; Palmer, E.; Suppes, T.; Cons, E.; Young, A.H.; Upthegrove, R. Novel and emerging treatments for major depression. Lancet 2022, 401, 141–153. [Google Scholar] [CrossRef]
  7. Reyad, A.A.; Plaha, K.; Girgis, E.; Mishriky, R. Fluoxetine in the Management of Major Depressive Disorder in Children and Adolescents: A Meta-Analysis of Randomized Controlled Trials. Hosp. Pharm. 2020, 56, 525–531. [Google Scholar] [CrossRef]
  8. Solmi, M.; Fornaro, M.; Ostinelli, E.G.; Zangani, C.; Croatto, G.; Monaco, F.; Krinitski, D.; Fusar-Poli, P.; Correll, C.U. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: A large scale systematic meta-review of 78 adverse effects. World Psychiatry 2020, 19, 214–232. [Google Scholar] [CrossRef]
  9. Oliva, V.; Lippi, M.; Paci, R.; Del Fabro, L.; Delvecchio, G.; Brambilla, P.; De Ronchi, D.; Fanelli, G.; Serretti, A. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2021, 109, 110266. [Google Scholar] [CrossRef]
  10. Boaden, K.; Tomlinson, A.; Cortese, S.; Cipriani, A. Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment. Front. Psychiatry 2020, 11, 717. [Google Scholar] [CrossRef]
  11. Li, W.; Ali, T.; He, K.; Liu, Z.; Shah, F.A.; Ren, Q.; Liu, Y.; Jiang, A.; Li, S. Ibrutinib alleviates LPS-induced neuroinflammation and synaptic defects in a mouse model of depression. Brain. Behav. Immun. 2021, 92, 10–24. [Google Scholar] [CrossRef]
  12. Zhao, X.; Cao, F.; Liu, Q.; Li, X.; Xu, G.; Liu, G.; Zhang, Y.; Yang, X.; Yi, S.; Xu, F.; et al. Behavioral, inflammatory and neurochemical disturbances in LPS and UCMS-induced mouse models of depression. Behav. Brain Res. 2019, 364, 494–502. [Google Scholar] [CrossRef]
  13. Rutsch, A.; Kantsjö, J.B.; Ronchi, F. The Gut-Brain Axis: How Microbiota and Host Inflammasome Influence Brain Physiology and Pathology. Front. Immunol. 2020, 11, 604179. [Google Scholar] [CrossRef]
  14. Murdaca, G.; Paladin, F.; Casciaro, M.; Vicario, C.M.; Gangemi, S.; Martino, G. Neuro-Inflammaging and Psychopathological Distress. Biomedicines 2022, 10, 2133. [Google Scholar] [CrossRef]
  15. Lu, A.-P.; Jia, H.-W.; Xiao, C.; Lu, Q.-P. Theory of traditional Chinese medicine and therapeutic method of diseases. World J. Gastroenterol. 2004, 10, 1854–1856. [Google Scholar] [CrossRef]
  16. Zhou, X.; Seto, S.W.; Chang, D.; Kiat, H.; Razmovski-Naumovski, V.; Chan, K.; Bensoussan, A. Synergistic Effects of Chinese Herbal Medicine: A Comprehensive Review of Methodology and Current Research. Front. Pharmacol. 2016, 7, 201. [Google Scholar] [CrossRef] [Green Version]
  17. Lv, S.; Zhao, Y.; Wang, L.; Yu, Y.; Li, J.; Huang, Y.; Xu, W.; Sun, G.; Dai, W.; Zhao, T.; et al. Antidepressant Active Components of Bupleurum chinense DC-Paeonia lactiflora Pall Herb Pair: Pharmacological Mechanisms. Bio. Med. Res. Int. 2022, 2022, 1024693. [Google Scholar] [CrossRef]
  18. Wang, Y.; Feng, D.-D.; Tang, T.; Lin, X.-P.; Yang, Z.-Y.; Yang, S.; Xia, Z.-A.; Wang, Y.; Zheng, P.; Zhang, C.-H. Nine traditional Chinese herbal formulas for the treatment of depression: An ethnopharmacology, phytochemistry, and pharmacology review. Neuropsychiatr Dis. Treat 2016, 12, 2387–2402. [Google Scholar] [CrossRef] [Green Version]
  19. Zhao, H.; Shan, Y.; Ma, Z.; Yu, M.; Gong, B. A network pharmacology approach to explore active compounds and pharmacological mechanisms of epimedium for treatment of premature ovarian insufficiency. Drug Des. Dev. Ther. 2019, 13, 2997–3007. [Google Scholar] [CrossRef] [Green Version]
  20. Singh, R.; Bhardwaj, V.K.; Purohit, R. Computational targeting of allosteric site of MEK1 by quinoline-based molecules. Cell Biochem. Funct. 2022, 40, 481–490. [Google Scholar] [CrossRef]
  21. Liu, J.; Li, F.; Tang, X.-D.; Ma, J.; Mao, M.; Wu, F.-Z.; Bai, S.-J.; Liu, Y.-Y.; Han, C.-X.; Li, X.-X.; et al. Sini powder (四逆散) decoction alleviates mood disorder of insomnia by regulating cation-chloride cotransporters in hippocampus. Chin. J. Integr. Med. 2015. [Google Scholar] [CrossRef]
  22. He, X.; Zhang, R.; Li, Z.; Yao, Z.; Xie, X.; Bai, R.; Li, L.; Zhang, X.; Zhang, S.; Shen, Y.; et al. Sini powder with paroxetine ameliorates major depressive disorder by modulating circadian rhythm: A randomized, double-blind, placebo-controlled trial. J. Pineal Res. 2022, 73, e12832. [Google Scholar] [CrossRef]
  23. Zhang, Q.; Du, S.T.; Ji, B.; Liu, F. Clinical Observation on Sini Powder Combined with Gan Mai Dazao Decoction in the Treatment of Type 2 Diabetes Mellitus Complicated with Depression and Anxiety. J. Guangzhou Univ. Tradit. Chin. Med. 2022, 39, 763–769. [Google Scholar] [CrossRef]
  24. Huang, X.Y. Observation on curative effect of Sini powder on functional dyspepsia with depression. Inn. Mong. J. Tradit. Chin. Med. 2022, 41, 39–40. [Google Scholar] [CrossRef]
  25. Liang, D.S. Efficacy on Affective Disorder and Dyskinesia Treated with Modified Sini San and Music Therapy in the Patients of Post-Stroke Depression. World J. Integr. West. Tradit. Med. 2016, 11, 1053–1056. [Google Scholar] [CrossRef]
  26. Wei, S.-S.; Yang, H.-J.; Huang, J.-W.; Lu, X.-P.; Peng, L.-F.; Wang, Q.-G. Traditional herbal formula Sini Powder extract produces antidepressant-like effects through stress-related mechanisms in rats. Chin. J. Nat. Med. 2016, 14, 590–598. [Google Scholar] [CrossRef]
  27. Pan, J.; Lei, X.; Wang, J.; Huang, S.; Wang, Y.; Zhang, Y.; Chen, W.; Li, D.; Zheng, J.; Cui, H.; et al. Effects of Kaixinjieyu, a Chinese herbal medicine preparation, on neurovascular unit dysfunction in rats with vascular depression. BMC Complement. Altern. Med. 2015, 15, 291. [Google Scholar] [CrossRef] [Green Version]
  28. Mu, J.; Cheng, F.; Wang, Q.; Wang, X.; Zhu, W.; Ma, C.; Yin, X.; Ren, B.; Lian, Y.; Du, X.; et al. Sini Powder Ameliorates the Inflammatory Response in Rats with Stress-Induced Non-Alcoholic Fatty Liver Disease by Inhibiting the Nuclear Factor Kappa-B / Pyrin Domain-Containing Protein 3 Pathway. J. Tradit. Chin. Med. 2020, 40, 253–266. [Google Scholar]
  29. Yan, X.; Zhang, Z.; Xu, F.; Li, Y.; Zhu, T.; Ma, C.; Liu, A. Effect of Sini San Freeze-dried powder on sleep-waking cycle in insomnia rats. J. Tradit. Chin. Med. 2014, 34, 572–575. [Google Scholar] [CrossRef] [Green Version]
  30. Li, X.; Qin, X.-M.; Tian, J.-S.; Gao, X.-X.; Du, G.-H.; Zhou, Y.-Z. Integrated network pharmacology and metabolomics to dissect the combination mechanisms of Bupleurum chinense DC-Paeonia lactiflora Pall herb pair for treating depression. J. Ethnopharmacol. 2020, 264, 113281. [Google Scholar] [CrossRef]
  31. Chen, J.; Li, T.; Qin, X.; Du, G.; Zhou, Y. Integration of Non-Targeted Metabolomics and Targeted Quantitative Analysis to Elucidate the Synergistic Antidepressant Effect of Bupleurum chinense DC-Paeonia lactiflora Pall Herb Pair by Regulating Purine Metabolism. Front. Pharmacol. 2022, 13, 900459. [Google Scholar] [CrossRef]
  32. Li, Q.-F.; Lu, W.-T.; Zhang, Q.; Zhao, Y.-D.; Wu, C.-Y.; Zhou, H.-F. Proprietary Medicines Containing Bupleurum chinense DC. (Chaihu) for Depression: Network Meta-Analysis and Network Pharmacology Prediction. Front. Pharmacol. 2022, 13, 773537. [Google Scholar] [CrossRef]
  33. Xue, B.; Zhao, Q.; Chen, D.; Wang, X.; Li, L.; Li, J.; Tian, J. Network Pharmacology Combined with Molecular Docking and Experimental Verification Reveals the Bioactive Components and Potential Targets of Danlong Dingchuan Decoction against Asthma. Evid. -Based Complement. Altern. Med. 2022, 2022, 7895271. [Google Scholar] [CrossRef]
  34. Press, B. Permeability for Intestinal Absorption: Caco-2 Assay and Related Issues. Curr. Drug Metab. 2008, 9, 893–900. [Google Scholar] [CrossRef]
  35. Ge, P.-Y.; Qi, Y.-Y.; Qu, S.-Y.; Zhao, X.; Ni, S.-J.; Yao, Z.-Y.; Guo, R.; Yang, N.-Y.; Zhang, Q.-C.; Zhu, H.-X. Potential Mechanism of S. baicalensis on Lipid Metabolism Explored via Network Pharmacology and Untargeted Lipidomics. Drug Des. Dev. Ther. 2021, 15, 1915–1930. [Google Scholar] [CrossRef]
  36. Chen, Q.; Gu, Y.; Tan, C.; Sundararajan, B.; Li, Z.; Wang, D.; Zhou, Z. Comparative effects of five polymethoxyflavones purified from Citrus tangerina on inflammation and cancer. Front. Nutr. 2022, 9, 963662. [Google Scholar] [CrossRef]
  37. Liu, Z.; Liu, R.; Wang, R.; Dai, J.; Chen, H.; Wang, J.; Li, X. Sinensetin attenuates IL-1β-induced cartilage damage and ameliorates osteoarthritis by regulating SERPINA3. Food Funct. 2022, 13, 9973–9987. [Google Scholar] [CrossRef]
  38. Zhi, Z.; Tang, X.; Wang, Y.; Chen, R.; Ji, H. Sinensetin Attenuates Amyloid Beta25-35-Induced Oxidative Stress, Inflammation, and Apoptosis in SH-SY5Y Cells Through the TLR4/NF-κB Signaling Pathway. Neurochem. Res. 2021, 46, 3012–3024. [Google Scholar] [CrossRef]
  39. Xu, Y.; Hang, W.-L.; Zhou, X.-M.; Wu, Q. Exploring the Mechanism Whereby Sinensetin Delays the Progression of Pulmonary Fibrosis Based on Network Pharmacology and Pulmonary Fibrosis Models. Front. Pharmacol. 2021, 12, 693061. [Google Scholar] [CrossRef]
  40. Yang, D.; Yang, R.; Shen, J.; Huang, L.; Men, S.; Wang, T. Sinensetin attenuates oxygen–glucose deprivation/reperfusion-induced neurotoxicity by MAPK pathway in human cerebral microvascular endothelial cells. J. Appl. Toxicol. 2021, 42, 683–693. [Google Scholar] [CrossRef]
  41. Kang, S.-I.; Shin, H.-S.; Kim, S.-J. Sinensetin Enhances Adipogenesis and Lipolysis by Increasing Cyclic Adenosine Monophosphate Levels in 3T3-L1 Adipocytes. Biol. Pharm. Bull. 2015, 38, 552–558. [Google Scholar] [CrossRef] [Green Version]
  42. Huang, Q.; Bai, F.; Nie, J.; Lu, S.; Lu, C.; Zhu, X.; Zhuo, L.; Lin, X. Didymin ameliorates hepatic injury through inhibition of MAPK and NF-κB pathways by up-regulating RKIP expression. Int. Immunopharmacol. 2017, 42, 130–138. [Google Scholar] [CrossRef]
  43. Zhang, Y.; RuXian, G. Didymin, a natural flavonoid, relieves the progression of myocardial infarction via inhibiting the NLR family pyrin domain containing 3 inflammasome. Pharm. Biol. 2022, 60, 2319–2327. [Google Scholar] [CrossRef]
  44. Li, Q.; Zhang, H.; Liu, X. Didymin Alleviates Cerebral Ischemia-Reperfusion Injury by Activating the PPAR Signaling Pathway. Yonsei Med. J. 2022, 63, 956–965. [Google Scholar] [CrossRef]
  45. Ali, Y.; Zaib, S.; Rahman, M.M.; Jannat, S.; Iqbal, J.; Park, S.K.; Chang, M.S. Didymin, a dietary citrus flavonoid exhibits anti-diabetic complications and promotes glucose uptake through the activation of PI3K/Akt signaling pathway in insulin-resistant HepG2 cells. Chem. Interact. 2019, 305, 180–194. [Google Scholar] [CrossRef]
  46. Theoharides, T.C.; Tsilioni, I. Tetramethoxyluteolin for the Treatment of Neurodegenerative Diseases. Curr. Top. Med. Chem. 2019, 18, 1872–1882. [Google Scholar] [CrossRef]
  47. Qin, Y.; Song, D.; Liao, S.; Chen, J.; Xu, M.; Su, Y.; Lian, H.; Peng, H.; Wei, L.; Chen, K.; et al. Isosinensetin alleviates estrogen deficiency-induced osteoporosis via suppressing ROS-mediated NF-κB/MAPK signaling pathways. Biomed. Pharmacother. 2023, 160, 114347. [Google Scholar] [CrossRef]
  48. Shi, Q.; Wang, J.; Cheng, Y.; Dong, X.; Zhang, M.; Pei, C. Palbinone alleviates diabetic retinopathy in STZ-induced rats by inhibiting NLRP3 inflammatory activity. J. Biochem. Mol. Toxicol. 2020, 34, e22489. [Google Scholar] [CrossRef]
  49. Bi, Y.; Han, X.; Lai, Y.; Fu, Y.; Li, K.; Zhang, W.; Wang, Q.; Jiang, X.; Zhou, Y.; Liang, H.; et al. Systems pharmacological study based on UHPLC-Q-Orbitrap-HRMS, network pharmacology and experimental validation to explore the potential mechanisms of Danggui-Shaoyao-San against atherosclerosis. J. Ethnopharmacol. 2021, 278, 114278. [Google Scholar] [CrossRef]
  50. Hu, P.-F.; Chen, W.-P.; Bao, J.-P.; Wu, L.-D. Paeoniflorin inhibits IL-1β-induced chondrocyte apoptosis by regulating the Bax/Bcl-2/caspase-3 signaling pathway. Mol. Med. Rep. 2018, 17, 6194–6200. [Google Scholar] [CrossRef]
  51. Lu, R.; Zhou, J.; Liu, B.; Liang, N.; He, Y.; Bai, L.; Zhang, P.; Zhong, Y.; Zhou, Y.; Zhou, J. Paeoniflorin ameliorates Adriamycin-induced nephrotic syndrome through the PPARγ/ANGPTL4 pathway in vivo and vitro. Biomed. Pharmacother. 2017, 96, 137–147. [Google Scholar] [CrossRef]
  52. Zhan, Y.; Wen, Y.; Zhang, L.-L.; Shen, X.-L.; Chen, X.-H.; Wu, X.-H.; Tang, X.-G. Paeoniflorin Improved Constipation in the Loperamide-Induced Rat Model via TGR5/TRPA1 Signaling-Mediated 5-Hydroxytryptamine Secretion. Evid. -Based Complement. Altern. Med. 2021, 2021, 6076293. [Google Scholar] [CrossRef]
  53. Qiu, Z.-K.; He, J.-L.; Liu, X.; Zeng, J.; Xiao, W.; Fan, Q.-H.; Chai, X.-M.; Ye, W.-H.; Chen, J.-S. Anxiolytic-like effects of paeoniflorin in an animal model of post traumatic stress disorder. Metab. Brain Dis. 2018, 33, 1175–1185. [Google Scholar] [CrossRef]
  54. Li, Y.C.; Zheng, X.X.; Xia, S.Z.; Li, Y.; Deng, H.H.; Wang, X.; Chen, Y.W.; Yue, Y.S.; He, J.; Cao, Y.J. Paeoniflorin ameliorates depressive-like behavior in prenatally stressed offspring by restoring the HPA axis- and glucocorticoid receptor- associated dysfunction. J. Affect. Disord. 2020, 274, 471–481. [Google Scholar] [CrossRef]
  55. Zhao, D.; Zhang, J.; Zhu, Y.; He, C.; Fei, W.; Yue, N.; Wang, C.; Wang, L. Study of Antidepressant-Like Effects of Albiflorin and Paeoniflorin Through Metabolomics From the Perspective of Cancer-Related Depression. Front. Neurol. 2022, 13, 828612. [Google Scholar] [CrossRef]
  56. Chen, Z.; Ma, X.; Zhu, Y.; Zhao, Y.; Wang, J.; Li, R.; Chen, C.; Wei, S.; Jiao, W.; Zhang, Y.; et al. Paeoniflorin ameliorates ANIT-induced cholestasis by activating Nrf2 through an PI3K/Akt-dependent pathway in rats. Phytother. Res. 2015, 29, 1768–1775. [Google Scholar] [CrossRef]
  57. Ha, D.T.; Phuong, T.T.; Oh, J.; Bae, K.; Thuan, N.D.; Na, M. Palbinone from Paeonia suffruticosa Protects Hepatic Cells via Up-regulation of Heme Oxygenase-1. Phytother. Res. 2013, 28, 308–311. [Google Scholar] [CrossRef]
  58. Liu, X.; Chen, K.; Zhuang, Y.; Huang, Y.; Sui, Y.; Zhang, Y.; Lv, L.; Zhang, G. Paeoniflorin improves pressure overload-induced cardiac remodeling by modulating the MAPK signaling pathway in spontaneously hypertensive rats. Biomed. Pharmacother. 2019, 111, 695–704. [Google Scholar] [CrossRef]
  59. Yu, M.; Wu, X.; Wang, J.; He, M.; Han, H.; Hu, S.; Xu, J.; Yang, M.; Tan, Q.; Wang, Y.; et al. Paeoniflorin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing TAK1-MAPK/NF-κB pathways. Int. J. Med. Sci. 2022, 19, 681–694. [Google Scholar] [CrossRef]
  60. Bai, Y.; He, Z.; Duan, W.; Gu, H.; Wu, K.; Yuan, W.; Liu, W.; Huang, H.; Li, Y. Sodium formononetin-3’-sulphonate alleviates cerebral ischemia–reperfusion injury in rats via suppressing endoplasmic reticulum stress-mediated apoptosis. BMC Neurosci. 2022, 23, 74. [Google Scholar] [CrossRef]
  61. Jia, C.; Hu, F.; Lu, D.; Jin, H.; Lu, H.; Xue, E.; Wu, D. Formononetin inhibits IL-1β-induced inflammation in human chondrocytes and slows the progression of osteoarthritis in rat model via the regulation of PTEN/AKT/NF-κB pathway. Int. Immunopharmacol. 2022, 113, 109309. [Google Scholar] [CrossRef]
  62. Sun, T.; Wang, J.; Huang, L.-H.; Cao, Y.-X. Antihypertensive effect of formononetin through regulating the expressions of eNOS, 5-HT2A/1B receptors and α1-adrenoceptors in spontaneously rat arteries. Eur. J. Pharmacol. 2013, 699, 241–249. [Google Scholar] [CrossRef]
  63. Li, T.; Zhong, Y.; Tang, T.; Luo, J.; Cui, H.; Fan, R.; Wang, Y.; Wang, D. Formononetin induces vasorelaxation in rat thoracic aorta via regulation of the PI3K/PTEN/Akt signaling pathway. Drug Des. Dev. Ther. 2018, 12, 3675–3684. [Google Scholar] [CrossRef] [Green Version]
  64. Wang, X.-Q.; Zhang, L.; Xia, Z.-Y.; Chen, J.-Y.; Fang, Y.; Ding, Y.-Q. PTEN in prefrontal cortex is essential in regulating depression-like behaviors in mice. Transl. Psychiatry 2021, 11, 185. [Google Scholar] [CrossRef]
  65. Yang, Y.; Huang, T.; Zhang, H.; Li, X.; Shi, S.; Tian, X.; Huang, Z.; Zhang, R.; Liu, Z.; Cheng, Y. Formononetin improves cardiac function and depressive behaviours in myocardial infarction with depression by targeting GSK-3β to regulate macrophage/microglial polarization. Phytomedicine 2023, 109, 154602. [Google Scholar] [CrossRef]
  66. Sugimoto, M.; Ko, R.; Goshima, H.; Koike, A.; Shibano, M.; Fujimori, K. Formononetin attenuates H2O2-induced cell death through decreasing ROS level by PI3K/Akt-Nrf2-activated antioxidant gene expression and suppressing MAPK-regulated apoptosis in neuronal SH-SY5Y cells. Neurotoxicology 2021, 85, 186–200. [Google Scholar] [CrossRef]
  67. Li, P.; Yu, C.; Zeng, F.-S.; Fu, X.; Yuan, X.-J.; Wang, Q.; Fan, C.; Sun, B.-L.; Sun, Q.-S. Licochalcone A Attenuates Chronic Neuropathic Pain in Rats by Inhibiting Microglia Activation and Inflammation. Neurochem. Res. 2021, 46, 1112–1118. [Google Scholar] [CrossRef]
  68. Chu, X.; Jiang, L.; Wei, M.; Yang, X.; Guan, M.; Xie, X.; Wei, J.; Liu, D.; Wang, D. Attenuation of allergic airway inflammation in a murine model of asthma by Licochalcone A. Immunopharmacol. Immunotoxicol. 2013, 35, 653–661. [Google Scholar] [CrossRef]
  69. Yang, G.; Lee, H.E.; Yeon, S.H.; Kang, H.C.; Cho, Y.-Y.; Zouboulis, C.C.; Han, S.-H.; Lee, J.-H.; Lee, J.Y. Licochalcone A attenuates acne symptoms mediated by suppression of NLRP3 inflammasome. Phytother. Res. 2018, 32, 2551–2559. [Google Scholar] [CrossRef]
  70. Zhu, W.; Wang, M.; Jin, L.; Yang, B.; Bai, B.; Mutsinze, R.N.; Zuo, W.; Chattipakorn, N.; Huh, J.Y.; Liang, G.; et al. Licochalcone A protects against LPS-induced inflammation and acute lung injury by directly binding with myeloid differentiation factor 2 (MD2). Br. J. Pharmacol. 2023, 180, 1114–1131. [Google Scholar] [CrossRef]
  71. Herbrechter, R.; Ziemba, P.M.; Hoffmann, K.M.; Hatt, H.; Werner, M.; Gisselmann, G. Identification of Glycyrrhiza as the rikkunshito constituent with the highest antagonistic potential on heterologously expressed 5-HT3A receptors due to the action of flavonoids. Front. Pharmacol. 2015, 6, 130. [Google Scholar] [CrossRef] [Green Version]
  72. Huang, W.-C.; Su, H.-H.; Fang, L.-W.; Wu, S.-J.; Liou, C.-J. Licochalcone A Inhibits Cellular Motility by Suppressing E-cadherin and MAPK Signaling in Breast Cancer. Cells 2019, 8, 218. [Google Scholar] [CrossRef] [Green Version]
  73. Guo, W.; Liu, B.; Yin, Y.; Kan, X.; Gong, Q.; Li, Y.; Cao, Y.; Wang, J.; Xu, D.; Ma, H.; et al. Licochalcone A Protects the Blood–Milk Barrier Integrity and Relieves the Inflammatory Response in LPS-Induced Mastitis. Front. Immunol. 2019, 10, 287. [Google Scholar] [CrossRef] [Green Version]
  74. Tian, M.; Li, N.; Liu, R.; Li, K.; Du, J.; Zou, D.; Ma, Y. The protective effect of licochalcone A against inflammation injury of primary dairy cow claw dermal cells induced by lipopolysaccharide. Sci. Rep. 2022, 12, 1593. [Google Scholar] [CrossRef]
  75. Bueno-Silva, B.; Rosalen, P.L.; Alencar, S.M.; Mayer, M.P. Vestitol drives LPS-activated macrophages into M2 phenotype through modulation of NF-κB pathway. Int. Immunopharmacol. 2020, 82, 106329. [Google Scholar] [CrossRef]
  76. Guo, J.; Li, J.; Wei, H.; Liang, Z. Maackiain Protects the Kidneys of Type 2 Diabetic Rats via Modulating the Nrf2/HO-1 and TLR4/NF-κB/Caspase-3 Pathways. Drug Des. Dev. Ther. 2021, 15, 4339–4358. [Google Scholar] [CrossRef]
  77. Zhu, X.; Shi, J.; Li, H. Liquiritigenin attenuates high glucose-induced mesangial matrix accumulation, oxidative stress, and inflammation by suppression of the NF-κB and NLRP3 inflammasome pathways. Biomed. Pharmacother. 2018, 106, 976–982. [Google Scholar] [CrossRef]
  78. Tao, W.; Dong, Y.; Su, Q.; Wang, H.; Chen, Y.; Xue, W.; Chen, C.; Xia, B.; Duan, J.; Chen, G. Liquiritigenin reverses depression-like behavior in unpredictable chronic mild stress-induced mice by regulating PI3K/Akt/mTOR mediated BDNF/TrkB pathway. Behav. Brain Res. 2016, 308, 177–186. [Google Scholar] [CrossRef]
  79. Su, Q.; Tao, W.; Huang, H.; Du, Y.; Chu, X.; Chen, G. Protective effect of liquiritigenin on depressive-like behavior in mice after lipopolysaccharide administration. Psychiatry Res. 2016, 240, 131–136. [Google Scholar] [CrossRef]
  80. Zhang, M.; Xue, Y.; Zheng, B.; Li, L.; Chu, X.; Zhao, Y.; Wu, Y.; Zhang, J.; Han, X.; Wu, Z.; et al. Liquiritigenin Protects against Arsenic Trioxide-Induced Liver Injury by Inhibiting Oxidative Stress and Enhancing MTOR-Mediated Autophagy. Biomed. Pharmacother. 2021, 143, 112167. [Google Scholar] [CrossRef]
  81. Li, Y.; He, X.; Zhang, J.; Zhou, Q.; Liu, X.; Zhou, G. Medicarpin Improves Depressive-Like Behaviors in a Chronic Unpredictable Mild Stress-Induced Mouse Model of Depression by Upregulating Liver X Receptor β Expression in the Amygdala. Neurotox. Res. 2022, 40, 1937–1947. [Google Scholar] [CrossRef]
  82. Wang, Y.; Yang, R.; Yan, F.; Jin, Y.; Liu, X.; Wang, T. Medicarpin Protects Cerebral Microvascular Endothelial Cells Against Oxygen-Glucose Deprivation/Reoxygenation-Induced Injury via the PI3K/Akt/FoxO Pathway: A Study of Network Pharmacology Analysis and Experimental Validation. Neurochem. Res. 2021, 47, 347–357. [Google Scholar] [CrossRef]
  83. Batiha, G.E.-S.; Beshbishy, A.M.; El-Mleeh, A.; Abdel-Daim, M.M.; Devkota, H.P. Traditional Uses, Bioactive Chemical Constituents, and Pharmacological and Toxicological Activities of Glycyrrhiza glabra L. (Fabaceae). Biomolecules 2020, 10, 352. [Google Scholar] [CrossRef] [Green Version]
  84. Kuroda, M.; Mimaki, Y.; Honda, S.; Tanaka, H.; Yokota, S.; Mae, T. Phenolics from Glycyrrhiza glabra roots and their PPAR-γ ligand-binding activity. Bioorganic Med. Chem. 2010, 18, 962–970. [Google Scholar] [CrossRef]
  85. Dogra, A.; Gupta, D.; Bag, S.; Ahmed, I.; Bhatt, S.; Nehra, E.; Dhiman, S.; Kumar, A.; Singh, G.; Abdullah, S.T.; et al. Glabridin ameliorates methotrexate-induced liver injury via attenuation of oxidative stress, inflammation, and apoptosis. Life Sci. 2021, 278, 119583. [Google Scholar] [CrossRef]
  86. Gao, H.; Peng, X.; Zhan, L.; Lin, J.; Zhang, Y.; Huan, Y.; Zhao, G. The role of Glabridin in antifungal and anti-inflammation effects in Aspergillus fumigatus keratitis. Exp. Eye Res. 2021, 214, 108883. [Google Scholar] [CrossRef]
  87. Zhang, J.; Wu, X.; Zhong, B.; Liao, Q.; Wang, X.; Xie, Y.; He, X. Review on the Diverse Biological Effects of Glabridin. Drug Des. Dev. Ther. 2023, 17, 15–37. [Google Scholar] [CrossRef]
  88. Chung, C.-L.; Chen, J.-H.; Huang, W.-C.; Sheu, J.-R.; Hsia, C.-W.; Jayakumar, T.; Hsia, C.-H.; Chiou, K.-R.; Hou, S.-M. Glabridin, a Bioactive Flavonoid from Licorice, Effectively Inhibits Platelet Activation in Humans and Mice. Int. J. Mol. Sci. 2022, 23, 11372. [Google Scholar] [CrossRef]
  89. Zhang, L.; Zhang, H.; Gu, J.; Xu, W.; Yuan, N.; Sun, J.; Li, H. Glabridin inhibits liver fibrosis and hepatic stellate cells activation through suppression of inflammation and oxidative stress by activating PPARγ in carbon tetrachloride-treated mice. Int. Immunopharmacol. 2022, 113, 109433. [Google Scholar] [CrossRef]
  90. Bader, G.D.; Hogue, C.W.V. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform. 2003, 4, 2–27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  91. Chen, X.; Huang, K.; Hu, S.; Lan, G.; Gan, X.; Gao, S.; Deng, Y.; Hu, J.; Li, L.; Hu, B.; et al. Integrated Transcriptome and Metabolome Analysis Reveals the Regulatory Mechanisms of FASN in Geese Granulosa Cells. Int. J. Mol. Sci. 2022, 23, 14717. [Google Scholar] [CrossRef]
  92. Kao, W.-Y.; Hsiang, C.-Y.; Ho, S.-C.; Ho, T.-Y.; Lee, K.-T. Novel serotonin-boosting effect of incense smoke from Kynam agarwood in mice: The involvement of multiple neuroactive pathways. J. Ethnopharmacol. 2021, 275, 114069. [Google Scholar] [CrossRef]
  93. Yao, W.; Cao, Q.; Luo, S.; He, L.; Yang, C.; Chen, J.; Qi, Q.; Hashimoto, K.; Zhang, J.-C. Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine. Mol. Psychiatry 2021, 27, 1618–1629. [Google Scholar] [CrossRef]
  94. Zhao, X.; Kong, D.; Zhou, Q.; Wei, G.; Song, J.; Liang, Y.; Du, G. Baicalein alleviates depression-like behavior in rotenone-induced Parkinson’s disease model in mice through activating the BDNF/TrkB/CREB pathway. Biomed. Pharmacother. 2021, 140, 111556. [Google Scholar] [CrossRef]
  95. Bazovkina, D.; Naumenko, V.; Bazhenova, E.; Kondaurova, E. Effect of Central Administration of Brain-Derived Neurotrophic Factor (BDNF) on Behavior and Brain Monoamine Metabolism in New Recombinant Mouse Lines Differing by 5-HT1A Receptor Functionality. Int. J. Mol. Sci. 2021, 22, 11987. [Google Scholar] [CrossRef]
  96. Gold, P.W. The PPARg System in Major Depression: Pathophysiologic and Therapeutic Implications. Int. J. Mol. Sci. 2021, 22, 9248. [Google Scholar] [CrossRef]
  97. Jiang, B.; Wang, Y.-J.; Wang, H.; Song, L.; Huang, C.; Zhu, Q.; Wu, F.; Zhang, W. Antidepressant-like effects of fenofibrate in mice via the hippocampal brain-derived neurotrophic factor signalling pathway. Br. J. Pharmacol. 2016, 174, 177–194. [Google Scholar] [CrossRef] [Green Version]
  98. Keller, J.; Gomez, R.; Williams, G.; Lembke, A.; Lazzeroni, L.; Murphy, G.M., Jr.; Schatzberg, A.F. HPA axis in major depression: Cortisol, clinical symptomatology and genetic variation predict cognition. Mol. Psychiatry 2017, 22, 527–536. [Google Scholar] [CrossRef]
  99. Gao, S.-F.; Bao, A.-M. Corticotropin-Releasing Hormone, Glutamate, and γ-Aminobutyric Acid in Depression. Neuroscientist 2010, 17, 124–144. [Google Scholar] [CrossRef]
  100. Choi, K.W.; Na, E.J.; Fava, M.; Mischoulon, D.; Cho, H.; Jeon, H.J. Increased adrenocorticotropic hormone (ACTH) levels predict severity of depression after six months of follow-up in outpatients with major depressive disorder. Psychiatry Res. 2018, 270, 246–252. [Google Scholar] [CrossRef]
  101. Song, J.; Zhou, N.; Ma, W.; Gu, X.; Chen, B.; Zeng, Y.; Yang, L.; Zhou, M. Modulation of gut microbiota by chlorogenic acid pretreatment on rats with adrenocorticotropic hormone induced depression-like behavior. Food Funct. 2019, 10, 2947–2957. [Google Scholar] [CrossRef]
  102. Xie, X.; Shen, Q.; Ma, L.; Chen, Y.; Zhao, B.; Fu, Z. Chronic corticosterone-induced depression mediates premature aging in rats. J. Affect. Disord. 2018, 229, 254–261. [Google Scholar] [CrossRef]
  103. Amigo, J.; Garro-Martinez, E.; Casado, R.V.; Compan, V.; Pilar-Cuéllar, F.; Pazos, A.; Díaz, A.; Castro, E. 5-HT4 Receptors Are Not Involved in the Effects of Fluoxetine in the Corticosterone Model of Depression. ACS Chem. Neurosci. 2021, 12, 2036–2044. [Google Scholar] [CrossRef]
  104. Gold, P.W.; Licinio, J.; Wong, M.-L.; Chrousos, G.P. Corticotropin Releasing Hormone in the Pathophysiology of Melancholic and Atypical Depression and in the Mechanism of Action of Antidepressant Drugs. Ann. New York Acad. Sci. 1995, 771, 716–729. [Google Scholar] [CrossRef]
  105. Pitchot, W.; Herrera, C.; Ansseau, M. HPA Axis Dysfunction in Major Depression: Relationship to 5-HT1A Receptor Activity. Neuropsychobiology 2001, 44, 74–77. [Google Scholar] [CrossRef]
  106. Jia, Z.; Yang, J.; Cao, Z.; Zhao, J.; Zhang, J.; Lu, Y.; Chu, L.; Zhang, S.; Chen, Y.; Pei, L. Baicalin ameliorates chronic unpredictable mild stress-induced depression through the BDNF/ERK/CREB signaling pathway. Behav. Brain Res. 2021, 414, 113463. [Google Scholar] [CrossRef]
  107. Wang, J.Q.; Mao, L. The ERK Pathway: Molecular Mechanisms and Treatment of Depression. Mol. Neurobiol. 2019, 56, 6197–6205. [Google Scholar] [CrossRef]
  108. Yang, B.; Wang, L.; Nie, Y.; Wei, W.; Xiong, W. proBDNF expression induces apoptosis and inhibits synaptic regeneration by regulating the RhoA-JNK pathway in an in vitro post-stroke depression model. Transl. Psychiatry 2021, 11, 578. [Google Scholar] [CrossRef]
  109. El Rawas, R.; Amaral, I.M.; Hofer, A. Is p38 MAPK Associated to Drugs of Abuse-Induced Abnormal Behaviors? Int. J. Mol. Sci. 2020, 21, 4833. [Google Scholar] [CrossRef]
  110. Lucassen, P.; Heine, V.; Muller, M.; van der Beek, E.; Wiegant, V.; De Kloet, E.R.; Joels, M.; Fuchs, E.; Swaab, D.; Czeh, B. Stress, Depression and Hippocampal Apoptosis. CNS Neurol. Disord. Drug Targets 2006, 5, 531–546. [Google Scholar] [CrossRef]
  111. Sun, Y.; Liu, Y.; Ma, X.; Hu, H. The Influence of Cell Cycle Regulation on Chemotherapy. Int. J. Mol. Sci. 2021, 22, 6923. [Google Scholar] [CrossRef]
  112. Patrício, P.; Mateus-Pinheiro, A.; Machado-Santos, A.R.; Alves, N.D.; Correia, J.S.; Morais, M.; Bessa, J.M.; Rodrigues, A.J.; Sousa, N.; Pinto, L. Cell Cycle Regulation of Hippocampal Progenitor Cells in Experimental Models of Depression and after Treatment with Fluoxetine. Int. J. Mol. Sci. 2021, 22, 11798. [Google Scholar] [CrossRef]
  113. Fronza, M.G.; Baldinotti, R.; Fetter, J.; Rosa, S.G.; Sacramento, M.; Nogueira, C.W.; Alves, D.; Praticò, D.; Savegnago, L. Beneficial effects of QTC-4-MeOBnE in an LPS-induced mouse model of depression and cognitive impairments: The role of blood-brain barrier permeability, NF-κB signaling, and microglial activation. Brain. Behav. Immun. 2021, 99, 177–191. [Google Scholar] [CrossRef]
  114. Cao, P.; Chen, C.; Liu, A.; Shan, Q.; Zhu, X.; Jia, C.; Peng, X.; Zhang, M.; Farzinpour, Z.; Zhou, W.; et al. Early-life inflammation promotes depressive symptoms in adolescence via microglial engulfment of dendritic spines. Neuron 2021, 109, 2573–2589. [Google Scholar] [CrossRef]
  115. Sun, Y.; Zhang, H.; Wu, Z.; Yu, X.; Yin, Y.; Qian, S.; Wang, Z.; Huang, J.; Wang, W.; Liu, T.; et al. Quercitrin Rapidly Alleviated Depression-like Behaviors in Lipopolysaccharide-Treated Mice: The Involvement of PI3K/AKT/NF-κB Signaling Suppression and CREB/BDNF Signaling Restoration in the Hippocampus. ACS Chem. Neurosci. 2021, 12, 3387–3396. [Google Scholar] [CrossRef]
  116. Guo, L.-T.; Wang, S.-Q.; Su, J.; Xu, L.-X.; Ji, Z.-Y.; Zhang, R.-Y.; Zhao, Q.-W.; Ma, Z.-Q.; Deng, X.-Y.; Ma, S.-P. Baicalin ameliorates neuroinflammation-induced depressive-like behavior through inhibition of toll-like receptor 4 expression via the PI3K/AKT/FoxO1 pathway. J. Neuroinflamm. 2019, 16, 95. [Google Scholar] [CrossRef] [Green Version]
  117. Zhang, X.-H.; Shen, C.-L.; Wang, X.-Y.; Xiong, W.-F.; Shang, X.; Tang, L.-Y.; Zhang, H.-X.; Wan, Y.-H.; Wu, Y.-B.; Fei, J.; et al. Increased Anxiety-like Behaviors in Adgra1−/− Male But Not Female Mice are Attributable to Elevated Neuron Dendrite Density, Upregulated PSD95 Expression, and Abnormal Activation of the PI3K/AKT/GSK-3β and MEK/ERK Pathways. Neuroscience 2022, 503, 131–145. [Google Scholar] [CrossRef]
  118. Cao, Q.; Zou, L.; Fan, Z.; Yan, Y.; Qi, C.; Wu, B.; Song, B. Ozone causes depressive-like response through PI3K/Akt/GSK3β pathway modulating synaptic plasticity in young rats. Ecotoxicol. Environ. Saf. 2022, 246, 114171. [Google Scholar] [CrossRef]
  119. Tóthová, Z.; Šemeláková, M.; Solárová, Z.; Tomc, J.; Debeljak, N.; Solár, P. The Role of PI3K/AKT and MAPK Signaling Pathways in Erythropoietin Signalization. Int. J. Mol. Sci. 2021, 22, 7682. [Google Scholar] [CrossRef]
  120. Rai, S.N.; Dilnashin, H.; Birla, H.; Singh, S.S.; Zahra, W.; Rathore, A.S.; Singh, B.K.; Singh, S.P. The Role of PI3K/Akt and ERK in Neurodegenerative Disorders. Neurotox. Res. 2019, 35, 775–795. [Google Scholar] [CrossRef]
Medicina 59 00741 g001 550
Figure 1. Enrichment analyses. (A) KEGG pathway enrichment analyses of SNP against depression, sorted by p-value. (B) The top 3 clusters of SNP, as identified using the MCODE algorithm.
Figure 1. Enrichment analyses. (A) KEGG pathway enrichment analyses of SNP against depression, sorted by p-value. (B) The top 3 clusters of SNP, as identified using the MCODE algorithm.
Medicina 59 00741 g001
Table
Table 1. Active components crossing the BBB of all 4 herbs of SNP.
Table 1. Active components crossing the BBB of all 4 herbs of SNP.
HerbMOL IDActive Component
CHMOL004644Sainfuran
MOL013187Cubebin
ZSMOL001803Sinensetin
MOL001941Ammidin
MOL005849Didymin
MOL007879Tetramethoxyluteolin
MOL013277Isosinensetin
MOL0132795,7,4’-Trimethylapigenin
MOL013430Prangenin
MOL013435Poncimarin
MOL013436Isoponcimarin
MOL0134376-Methoxy aurapten
BSMOL001919Palbinone
MOL001925Paeoniflorin
GCMOL000392Formononetin
MOL000497Licochalcone a
MOL000500Vestitol
MOL001484Maackiain
MOL001792Liquiritigenin
MOL002565Medicarpin
MOL0038967-Methoxy-2-methyl isoflavone
MOL004815Kanzonol B
MOL004833Phaseolinisoflavan
MOL004835Glypallichalcone
MOL004838Kanzonol U
MOL004891Shinpterocarpin
MOL004908Glabridin
MOL004910Glabranin
MOL004911Glabrene
MOL004941(2R)-7-hydroxy-2-(4-hydroxyphenyl)chroman-4-one
MOL004945Isobavachin
MOL004957Isoformononetin
MOL0049591-Methoxyphaseollidin
MOL0049663’-Hydroxy-4’-O-Methylglabridin
MOL0049743’-Methoxyglabridin
MOL0049784’-Methoxyglabridin
MOL004980Inflacoumarin A
MOL004988Kanzonol F
MOL0049917-Acetoxy-2-methylisoflavone
Table
Table 2. Top 3 clusters identified from the MCODE results of SNP.
Table 2. Top 3 clusters identified from the MCODE results of SNP.
ClusterPathway DescriptionNumber of TargetsNumber of EdgesScore
1Apoptosis3450230.424
2Cell cycle5141516.600
3PI3K-Akt signaling pathway5528310.481
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Shen, Z.; Yu, M.; Dong, Z. Research Progress on the Pharmacodynamic Mechanisms of Sini Powder against Depression from the Perspective of the Central Nervous System. Medicina 2023, 59, 741. https://doi.org/10.3390/medicina59040741

AMA Style

Shen Z, Yu M, Dong Z. Research Progress on the Pharmacodynamic Mechanisms of Sini Powder against Depression from the Perspective of the Central Nervous System. Medicina. 2023; 59(4):741. https://doi.org/10.3390/medicina59040741

Chicago/Turabian Style

Shen, Zhongqi, Meng Yu, and Zhenfei Dong. 2023. "Research Progress on the Pharmacodynamic Mechanisms of Sini Powder against Depression from the Perspective of the Central Nervous System" Medicina 59, no. 4: 741. https://doi.org/10.3390/medicina59040741

Article Metrics

Back to TopTop